Highlights•CAR T cell clinical trial manufacturing data is investigated.•Three dominant
process routes are uncovered.•The trend in CAR T cell manufacturing is towards …

Adoptive cellular immunotherapy using immune cells expressing chimeric antigen receptors
(CARs) has shown promise, particularly for the treatment of hematological malignancies. To …

Clinical trials of adoptively transferred CD19 chimeric antigen receptor (CAR) T cells have
delivered unprecedented responses in patients with relapsed refractory B-cell malignancy …

Chimeric antigen receptor (CAR) T-cells represent a paradigm shift in cancer
immunotherapy and a new milestone in the history of oncology. In 2017, the Food and Drug …

Simple Summary Chimeric antigen receptor (CAR) therapy has increased treatment options
for many patients who have failed standard chemotherapy. So far, CAR therapy has been …

Donor lymphocyte infusion has been used in the management of relapsed hematologic
malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal …

Although second allogeneic haematopoietic cell transplantation (allo‐HCT 2) is a
therapeutic option for patients relapsing after first HCT (allo‐HCT 1), there is limited data on …

Chimaeric antigen receptor T‐cell (CAR T) therapy has revolutionized the management of
many haematological malignancies. It is associated with impressive disease responses in …

Introduction: Various settings of acute lymphoblastic leukemia (ALL) represent unmet
medical needs: first remission at high risk of relapse, such as persistent minimal residual …

Cancer treatment has traditionally focused on eliminating tumor cells but faces challenges
such as resistance and toxicity. A promising direction involves targeting the tumor …